London, UK 9/27/18—LGC has purchased Berry and Associates, which sells specialty oligo reagents to pharmaceutical, clinical diagnostics and academic research customers, oligonucleotide synthesis firms, and CMOs. “Berry and Associates is a natural US counterpart to our UK-based LINK business and it will become an important center for our North America business,” commented Brian Kim, president and managing director, Genomics division, LGC. “Furthermore, Berry and Associates will increase supply chain resilience for our customers through multi-site manufacturing as well as local customer service and technical support in the US market.” Based in Michigan, Berry and Associates has 14 employees. Its product lines include more than 400 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis, as well as nucleosides, spacers, fluorescent markers, quenchers and heterocycles.

The company will become part of LGC’s NAC (Nucleic Acid Chemistry) business unit, part of its Genomics division. Consisting of the Genomics division and Standards division, LGC generated £331.2 million ($441.6 million = £0.75 = $1) in sales for the year ending March 31, a 17.7% increase (see Bottom Line). LGC’s NAC business also includes Biosearch Technologies, Prime Synthesis, LINK Technologies and BioAutomation.